Phase I, Open-label, Dose-Escalation Study of SNX-5422 Plus Everolimus in Neuroendocrine Tumors (NETs) Gutierrez, M. E., Giaccone, G., Liu, S. V., Rajan, A., Guha, U., Halfdanarson, T., Kunz, P., Hinson, J. M., Orlemans, E. O. LIPPINCOTT WILLIAMS & WILKINS. 2018: 339

View details for Web of Science ID 000426086300044